T2D injectables: 1. Intensifying to first injectable therapy in uncomplicated type 2 diabetes
You need to login to participate in this education.
This education is accredited: RACGP 2 CPD, ACRRM 2 CME PD.
This is one module of the T2D injectables series of education, which is also available as the 5-hour Accredited CPD Activity Rethinking first injectable therapies in type 2 diabetes: A practical approach.
This education module focuses on a case study of an uncomplicated patient with type 2 diabetes, and the process of intensifying to first injectable therapy. Expert video commentary throughout the module helps step the participant through the decision cycle from the ADA/EASD consensus guidelines for T2D. This module also includes Australian recommendations for patients fasting during Ramadan.
On completion of this education activity participants will be able to:
- Apply principles of patient-centred glycaemic management in type 2 diabetes to help choose a suitable first injectable therapy for a patient with uncontrolled type 2 diabetes, without existing atherosclerotic cardiovascular disease (ASCVD).
- Explain the difference between a GLP-1 RA therapy and insulin therapy to a patient.
- Outline latest recommendations for managing injectable therapies to avoid hypoglycaemia in patients who plan to fast during Ramadan.
- Apply recommendations for regular reassessment of cardiovascular risk in a patient with type 2 diabetes.
This activity is sponsored by Eli Lilly Australia.
|T2D injectables: 1 - Education|
|T2D injectables: 1 - Evaluation|